PubRank

Kim-Anh Do

Author PubWeight™ 108.93‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008 6.39
2 Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005 4.06
3 Steps toward mapping the human vasculature by phage display. Nat Med 2002 3.82
4 Simplified staging for hepatocellular carcinoma. J Clin Oncol 2002 3.48
5 Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat Biotechnol 2002 3.32
6 Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood 2007 2.91
7 Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 2011 2.64
8 Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst 2009 2.34
9 Body surface area and body weight predict total liver volume in Western adults. Liver Transpl 2002 2.21
10 Obesity, weight gain, and risk of biochemical failure among prostate cancer patients following prostatectomy. Clin Cancer Res 2005 2.14
11 Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. J Clin Oncol 2011 1.96
12 PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clin Cancer Res 2012 1.83
13 A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Sci Transl Med 2011 1.74
14 Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol 2006 1.67
15 Synchronous selection of homing peptides for multiple tissues by in vivo phage display. FASEB J 2006 1.63
16 Association and interactions between DNA repair gene polymorphisms and adult glioma. Cancer Epidemiol Biomarkers Prev 2009 1.51
17 Biomarkers of response to Akt inhibitor MK-2206 in breast cancer. Clin Cancer Res 2012 1.44
18 Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer. Clin Cancer Res 2007 1.42
19 Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. J Clin Oncol 2008 1.40
20 Treatment outcomes of small cell carcinoma of the prostate: a single-center study. Cancer 2007 1.39
21 Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer. J Natl Cancer Inst 2006 1.39
22 Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy. Cancer Prev Res (Phila) 2010 1.35
23 Preoperative predictors of survival after resection of small hepatocellular carcinomas. Ann Surg 2002 1.35
24 A Bayesian semiparametric survival model with longitudinal markers. Biometrics 2009 1.29
25 Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment. J Clin Oncol 2009 1.27
26 Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies. Cancer 2004 1.27
27 Bayesian ensemble methods for survival prediction in gene expression data. Bioinformatics 2010 1.24
28 Relationship between epidemiologic risk factors and breast cancer recurrence. J Clin Oncol 2007 1.21
29 Rapamycin regulates stearoyl CoA desaturase 1 expression in breast cancer. Mol Cancer Ther 2010 1.21
30 Ligand-directed surface profiling of human cancer cells with combinatorial peptide libraries. Cancer Res 2006 1.17
31 Serum organochlorine levels and history of lactation in Egypt. Environ Res 2003 1.16
32 Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center. J Clin Oncol 2007 1.15
33 iBAG: integrative Bayesian analysis of high-dimensional multiplatform genomics data. Bioinformatics 2012 1.14
34 Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia. J Clin Oncol 2011 1.12
35 Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease. Br J Haematol 2003 1.03
36 Targeting the EGFR, VEGFR, and PDGFR on colon cancer cells and stromal cells is required for therapy. Clin Exp Metastasis 2008 1.02
37 Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer. Breast Cancer Res 2012 1.01
38 Gene expression, molecular class changes, and pathway analysis after neoadjuvant systemic therapy for breast cancer. Clin Cancer Res 2012 1.00
39 Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer 2006 0.97
40 High stearoyl-CoA desaturase 1 expression is associated with shorter survival in breast cancer patients. Breast Cancer Res Treat 2012 0.97
41 Serum levels of insulin growth factor (IGF-I) and IGF-binding protein predict risk of second primary tumors in patients with head and neck cancer. Clin Cancer Res 2004 0.96
42 Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer. Cancer 2012 0.96
43 Bagged gene shaving for the robust clustering of high-throughput data. Int J Bioinform Res Appl 2010 0.95
44 A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens. Cancer 2006 0.94
45 Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia. Blood 2005 0.93
46 Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer. Clin Cancer Res 2004 0.93
47 Therapy of multidrug resistant human prostate tumors in the prostate of nude mice by simultaneous targeting of the epidermal growth factor receptor and vascular endothelial growth factor receptor on tumor-associated endothelial cells. Prostate 2006 0.92
48 Prospective study of incidence and severity of epiphora and canalicular stenosis in patients with metastatic breast cancer receiving docetaxel. J Clin Oncol 2006 0.92
49 Effect of low-fat diets on plasma levels of NF-κB-regulated inflammatory cytokines and angiogenic factors in men with prostate cancer. Cancer Prev Res (Phila) 2011 0.92
50 Semiparametric Bayesian inference for phage display data. Biometrics 2013 0.90
51 A dose-finding study of aspirin for chemoprevention utilizing rectal mucosal prostaglandin E(2) levels as a biomarker. Cancer Epidemiol Biomarkers Prev 2002 0.90
52 Presalvage prostate-specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapy. Cancer 2006 0.90
53 Is patient age a factor in the occurrence of prostate-specific antigen bounce phenomenon after external beam radiotherapy for prostate cancer? Urology 2005 0.89
54 In vivo imaging of prostate cancer involving bone in a mouse model. Prostate 2007 0.89
55 Morphologic characterization of preoperatively treated prostate cancer: toward a post-therapy histologic classification. Eur Urol 2009 0.88
56 Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer. Clin Cancer Res 2008 0.87
57 Employing the treatment-free interval of intermittent androgen ablation to screen candidate prostate cancer therapies. Prostate 2007 0.87
58 Joint effect of mutagen sensitivity and insulin-like growth factors in predicting the risk of developing secondary primary tumors and tumor recurrence in patients with head and neck cancer. Clin Cancer Res 2006 0.87
59 Integrative network-based Bayesian analysis of diverse genomics data. BMC Bioinformatics 2013 0.86
60 Dicarbonyl/L-xylulose reductase: a potential biomarker identified by laser-capture microdissection-micro serial analysis of gene expression of human prostate adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2007 0.86
61 Prognostic value of single nucleotide polymorphisms of candidate genes associated with inflammation in early stage breast cancer. Breast Cancer Res Treat 2013 0.86
62 Polymorphisms in genes involved in neurodevelopment may be associated with altered brain morphology in schizophrenia: preliminary evidence. Psychiatry Res 2008 0.86
63 Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma. Leuk Res 2004 0.85
64 Association between germline single nucleotide polymorphisms in the PI3K-AKT-mTOR pathway, obesity, and breast cancer disease-free survival. Breast Cancer Res Treat 2014 0.84
65 Biochemical disease-free survival in men younger than 60 years with prostate cancer treated with radical prostatectomy. Urology 2006 0.84
66 Biomarker expression patterns that correlate with high grade features in treatment naive, organ-confined prostate cancer. BMC Med Genomics 2008 0.84
67 How to get the most from microarray data: advice from reverse genomics. BMC Genomics 2014 0.84
68 Clinical and biomarker correlates of androgen-independent, locally aggressive prostate cancer with limited metastatic potential. Clin Cancer Res 2004 0.83
69 Genetic variants in the vitamin D pathway and breast cancer disease-free survival. Carcinogenesis 2012 0.82
70 Combined laser capture microdissection and serial analysis of gene expression from human tissue samples. Mod Pathol 2005 0.80
71 Fitting genetic models to twin data with binary and ordered categorical responses: a comparison of structural equation modelling and Bayesian hierarchical models. Behav Genet 2003 0.80
72 Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma. Cancer 2006 0.80
73 Immediate versus staged urethrectomy in patients at high risk of urethral recurrence: is there a benefit to either approach? Urology 2006 0.80
74 Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers. Cancer 2011 0.80
75 Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemia. Br J Haematol 2003 0.79
76 Diet modification and metformin have a beneficial effect in a fly model of obesity and mucormycosis. PLoS One 2014 0.79
77 Quantification of mineralized bone response to prostate cancer by noninvasive in vivo microCT and non-destructive ex vivo microCT and DXA in a mouse model. PLoS One 2010 0.78
78 Differences in gene and protein expression and the effects of race/ethnicity on breast cancer subtypes. Cancer Epidemiol Biomarkers Prev 2013 0.78
79 Genomic copy number imbalances associated with bone and non-bone metastasis of early-stage breast cancer. Breast Cancer Res Treat 2013 0.77
80 Redirecting T-Cell Specificity to EGFR Using mRNA to Self-limit Expression of Chimeric Antigen Receptor. J Immunother 2016 0.76
81 Model averaging strategies for structure learning in Bayesian networks with limited data. BMC Bioinformatics 2012 0.76
82 Extracellular and intracellular mechanisms that mediate the metastatic activity of exogenous osteopontin. Cancer 2009 0.76
83 Bayesian decision theoretic multiple comparison procedures: an application to phage display data. Biom J 2012 0.75
84 Correction: Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes. PLoS One 2016 0.75
85 Biostatistical approaches for modeling longitudinal and event time data. Clin Cancer Res 2002 0.75
86 Enhanced suppression of prostate tumor growth by combining C-CAM1 gene therapy and angiogenesis inhibitor TNP-470. Anticancer Drugs 2002 0.75
87 Building networks with microarray data. Methods Mol Biol 2010 0.75